



<https://doi.org/10.15446/cr.v4n2.69047>

MULTIPLE MYELOMA AND LIGHT-CHAIN AMYLOIDOSIS: A RARE PRESENTATION

Keywords: Amyloidosis; Multiple Myeloma; Myositis; Respiratory Insufficiency.
Palabras clave: Amiloidosis; Mieloma múltiple; Miositis; Insuficiencia respiratoria.

Carmenza Liliana Sandoval

Universidad Nacional de Colombia
- Bogotá Campus- Faculty of Medicine -
Department of Internal Medicine
- Bogotá D.C. - Colombia

Bernarda Jinneth Acosta

Universidad Nacional de Colombia
- Bogotá Campus - Faculty of Medicine -
Department of Pathology
- Bogotá D.C. - Colombia.

Óscar Contreras

Hospital Universitario Nacional de Colombia
- Adult Intensive Care Unit
- Bogotá D.C. - Colombia.

Jorge Vargas

EPS SURA - IPS Olaya -
Outpatient Consultation
- Bogotá D.C. - Colombia.

Corresponding author:

Carmenza Liliana Sandoval. Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia. Email: calisari87@gmail.com.

RESUMEN

Introducción. La amiloidosis sistémica primaria hace parte del espectro de neoplasias de células plasmáticas, donde las cadenas livianas de inmunoglobulina se depositan en múltiples órganos. El compromiso miopático con falla respiratoria y mieloma múltiple asociado es poco frecuente.

Caso clínico. Se presenta el caso de un paciente con amiloidosis sistémica de cadenas livianas (AL) quien ingresó por miopatía con falla respiratoria e íleo adinámico, por lo que se llevó a la unidad de cuidados intensivos. Por histología se confirmó infiltración en piel y tracto digestivo y concomitantemente se presentó mieloma múltiple con lesiones óseas líticas y riñón de mieloma. El paciente tuvo buena respuesta al esquema CyBorD (ciclofosfamida, bortezomib, dexametasona), recuperó su función renal y tuvo disminución de las lesiones en piel. Sin embargo, el compromiso gastrointestinal y miopático fue difícil de manejar y se requirió soporte ventilatorio y nutrición parenteral.

Discusión. El clínico puede pasar por alto esta patología, por lo que es probable llegar a fases avanzadas de la enfermedad. En la actualidad, con nuevos agentes de quimioterapia y trasplante autólogo, se puede aumentar la sobrevivencia de estos pacientes.

Conclusión. La amiloidosis AL tiene un amplio espectro de manifestaciones y debe considerarse en los diagnósticos diferenciales a fin de hacer un diagnóstico precoz y hacerla una condición tratable.

ABSTRACT

Introduction: Primary systemic amyloidosis is part of the spectrum of plasma cell neoplasms, in which immunoglobulin light chains are deposited in multiple organs. However, myopathic involvement along with respiratory failure and associated multiple myeloma is a rare condition.

Clinical case: This paper presents the case of a patient with systemic light chain amyloidosis who was admitted due to myopathy with respiratory failure and adynamic ileus that required intensive care. Infiltration in skin and digestive tract was confirmed by histology. The patient presented with concomitant multiple myeloma with lytic bone lesions and myeloma kidney. The patient responded well to the CyBorD scheme (cyclophosphamide, bortezomib, dexamethasone), renal function was recovered and skin lesions decreased. However, gastrointestinal and myopathic involvement was difficult to manage, requiring ventilatory support and parenteral nutrition.

Discussion: Clinicians may oversee this pathology, leading to advanced stages of the disease. Currently, new chemotherapy agents and autologous transplantation may increase the survival of these patients.

Conclusion: AL amyloidosis has a wide spectrum of manifestations and should be considered in differentials to reach an early diagnosis and make it treatable.

INTRODUCTION

Amyloidosis comprises a heterogeneous group of diseases characterized by protein deposition (27 different types) that adopt a crossed β structure to form amyloid fibrils in the extracellular space. Primary systemic amyloidosis (amyloid light-chain, or AL) is one of them and is part of the spectrum of plasma cell neoplasms, in which an aberrant clone (<20% of plasma cells in the bone marrow) exaggeratedly produces immunoglobulin light chains (more frequently lambda), forming amyloid. (1) In the USA, the estimated annual incidence is

3 000 cases (2), the age at onset varies between the fourth and seventh decade of life, and is predominant in men. (3) Some patients may develop localized amyloidosis in the genitourinary or respiratory tract, in the lymph nodes or in the conjunctiva. (4,5)

Its pathophysiology is still not completely clear: the damage is the result of mechanical interference and amyloid accumulation in the extracellular matrix of the vessels with apoptosis and ischemic damage. (6,3) The first tissues to be affected are blood vessels, which generates early endothelial microcirculatory dysfunction. (6) AL amyloidosis is associated in 10-15% of multiple myeloma cases and may be preceded by it or developed concomitantly (7); a similar proportion of patients with multiple myeloma will develop asymptomatic amyloid deposition. (3,8) In general, this pathology can affect any organ, except the brain (4), and the most common presentations are nephrotic syndrome, cardiomyopathy, peripheral sensory-motor neuropathy and hepatomegaly. (6,9) The following is the case of a patient with systemic AL amyloidosis and concomitant multiple myeloma who presented with respiratory failure and adynamic ileus.

CASE PRESENTATION

Male, mestizo patient, aged 47 years, from Bogotá D.C., meat vendor, who consulted for dyspnea and muscle weakness. Functional classification had decreased progressively for 18 months and worsened in the last 3 months, reaching the IV/IV classification on the NYHA scale, which is associated with orthopnea and lower limb edema. The patient presented with shoulder myalgia and gradual reduction of proximal muscle strength 11 months before consultation, with no paroxysmal nocturnal dyspnea. On examination, moderate to severe pulmonary hypertension and restriction in spirometry were found with mild oxygenation and hypercapnia disorder associated with obstructive sleep apnea-hypopnea syndrome (apnea/hypopnea index: 8.7). Chronic thromboembolic pulmonary hypertension (CTEPH) was ruled out with ventilation/perfusion scan. Only class 1 obesity was reported as a pre-existing medical condition. The systems review revealed purplish eyelids and a mass in the perineal region—which increased with valsalva maneuvers—, abdominal distension, dysphagia to solids, constipation, erectile dysfunction and paresthesia of the hands.

On physical examination, the patient had a reading of 73% of arterial oxygen desaturation and positive purplish upper eyelids (raccoon eye) (Figure 1), class 2 jugular venous pressure, grade 2 systolic murmur in the tricuspid area, abdominal distension and decreased bowel sounds. A non-pruritic, non-painful tumor that bled easily was observed in the perineal skin (Figure 2). Grade II edema in lower limbs, decreased proximal muscle strength and single-breath counting of 12 (normal range ≥ 20) were also reported without muscle fatigability. Muscle

hypertrophy of the bilateral supraspinus, bilateral deltoids and forearm muscles with pseudohypertrophy of paraspinal muscles were also evidenced.



Figure 1. A. Periorbital ecchymosis. B. Periumbilical purpuric macules.

Source: Own elaboration based on the data obtained in the study



Figure 2. Hyperpigmentation and perineal tumor, and scrotal infiltration.

Source: Own elaboration based on the data obtained in the study.

On admission, myopathy studies were initiated (Table 1) and muscle enzymes, electromyography and muscle biopsy were requested, which excluded inflammatory myopathy. The autoimmune profile and HIV were negative. Adult Pompe disease was considered, but acid maltase was normal and syringomyelia was ruled out using contrast-enhanced cervical

and brain MRI (Figure 3). Considering the lytic lesions observed in chest tomography, neoplasms (myopathy as a paraneoplastic phenomenon) were looked for as there was no compromise of the pulmonary parenchyma, only bibasal subsegmental atelectasis. No masses or organomegaly were observed in abdomen images (Figure 4).

Table 1. Summary of the main paraclinical tests of the case.

Name of the test and reference values		Results
Complete blood count	Leukocytes 4.8-10 ³ uL	8.850/uL
	Hemoglobin 14-18 g/dL	11.9 g/dL

Continues.

Name of the test and reference values		Results
Complete blood count	Hematocrit 45-54	27.6
	Platelets 150-450 ³ u/L	268000/uL
Renal function	Creatinine 0.6-1.24 mg/dl	On admission: 0.8 mg/dL After 12 days: 3.84 mg/dL
	BUN 6-20 mg/dL	On admission: 11 mg/dL After 12 days: 40 mg/dL
Transaminases	SGOT 15-41 u/L	29.3 u/L
	GPT 17-63 u/L	12.1 u/L
Bilirubin	Total 0.3-1.2 mg/dL	0.76 mg/dL
	Direct 0.1-0.5	0.3 mg/dL
Lactic dehydrogenase 105-300 u/L		265 u/L
Electrolytes	Potassium 3.5-5.1 meq/L	4.04 meq/L
	Calcium 1.16-1.32 mmol/L	1.26 mmol/L
	Sodium 135-145meq/L	142 meq/L
Total proteins 6.1-7.9 g/dL		5.5 g/dL
Albumin 3.5-4.8 g/dL		3.8 g/dL
ESR 0-15 mm/hour		38 mm/hour
CPK 39.0-308.0 UI/L		248 UI/L
Alkaline phosphatase 40.0-129.0 UI/L		88 UI/L
Hormonal tests	TSH 0.4-10 uui/mL	9.83 uui/mL
	Free T4 1.0-1.7 ng/dL	1.05 ng/ dL
	Prolactin 4-15.2 ng/mL	41.58 ng/mL
	Testosterone 4-30 pg/mL	1.4 pg/mL
	Cortisol am 10-20 ug/dL	10.5 ug/dL
	PTH 15 - 65 pg/mL	50.8 pg/mL
24-hour urine protein		3510 mg/24h
Protein electrophoresis and immunofixation		Hypogammaglobulinemia and lambda mono-clonal peak
Lambda free light chains 5.71-26.30 mg/L		1146.12mg/L
Kappa free light chains 3.30-19.40 mg/L		15.70 mg/L
Beta-2 microglobulin 0.80-2.20 mg/L		19.46 mg/L
proBNP 10-53 pg/mL		1580pg/mL
Troponin T 0.000 - 0.013 ng/mL		0.177 ng/mL
Electromyography and nerve conduction velocity		Generalized myopathy, bilateral carpal tunnel syndrome
Bone survey		Lytic lesions in right humeral head, skull, T8, L3, sternum and 6th left costal arch

Continues.

Name of the test and reference values	Results
Transthoracic echocardiogram	Severe moderate concentric hypertrophy VI, mild systolic dysfunction with changes in myocardial texture, moderately dilated RV with free wall hypertrophy (10mm) and moderate PHT, SPAP 59 mmhg, TAPSE 22mmHg and septum of 18mm
Esophageal motility test	Mild pharyngeal hypomotility and mild motor dysphagia

RV: right ventricle; LV: left ventricle; TAPSE: tricuspid annular plane systolic excursion; SPAP: systolic pulmonary arterial pressure; PH: pulmonary hypertension.

Source: Own elaboration.




Figure 3. Contrast-enhanced MRI of the head and neck, coronal plane, with paraspinal muscular edema.

Source: Own elaboration based on the data obtained in the study.



Figure 4. Sagittal CT scan of contralateral abdomen: distended loops and lytic lesions in T8 and L3 (arrows).

Source: Own elaboration based on the data obtained in the study.

One week after admission, the patient presented acute kidney injury classified as stage 3 KDIGO (discarding prerenal origin, pharmacological toxicity and obstruction) and hypoxemic and hypercapnic respiratory failure, so he was transferred to the intensive care unit (ICU) for invasive mechanical ventilation and initiation of dialysis. Considering the presence of lytic bone lesions and hyperazotemia with nephrotic-range proteinuria by Bence Jones protein filtration, bone marrow aspiration and biopsy were per-

formed, finding 80% of plasma cells (Figure 5). Lambda light chain multiple myeloma ISS III was diagnosed (Table 1). However, a colonoscopy was performed as the patient presented with myopathy, skin lesions, bilateral carpal tunnel, infiltrative cardiomyopathy, hypogonadism, erectile dysfunction and adynamic ileus that were not explained by the myeloma (Figure 6), finding extremely friable mucosa; perineal lesion and renal biopsy were taken to establish the presence of associated systemic amyloidosis.




Figure 5. Bone marrow aspirate, 40x lens with plasmocytes, some atypical binucleated cells, eccentric nucleus, broad and basophilic cytoplasm.

Source: Own elaboration based on the data obtained in the study.




Figure 6. Colonoscopy. A) Submucosal hematoma and multiple mucosal ecchymoses; B) congestive mucosa and ulcer covered by fibrin.

Source: Own elaboration based on the data obtained in the study.

AL amyloidosis was confirmed by perianal lesion and colonic mucosa biopsy (Figures 7, 8, 9 and 10), where a deposit of eosinophilic amorphous material was found in the submucosa and vessel wall with the typical apple-green birefringence of Congo Red stained preparations under polarized light and confirmed with immunohistochemistry. Renal biopsy showed tubulopathy due to lambda free chain deposits, along with amyloid deposits in arterioles.

Chemotherapy following the CyBorD scheme was initiated due to the diagnosis of multiple myeloma with associated AL amyloidosis and the important systemic involvement in the patient. 20 days after the first cycle of chemotherapy, the subject was taken off

dialysis. During the second cycle, bortezomib was discontinued and the dose of steroids was decreased to avoid potentiating its side effects (myopathy and neuropathy). Until that moment, the patient still depended on the ventilator due to a tracheostomy and required support pressure due to muscle fatigability. Adynamic ileus did not respond to multiple prokinetics nor neostigmine; enteral nutrition was maintained for trophic stimulation and total parenteral nutrition. After 4 months in the ICU connected to the ventilator with nutritional support and after four cycles of chemotherapy, the patient died due to ventilator-associated pneumonia and bacteremia due to *Klebsiella pneumoniae*, producer of carbapenemases.




Figure 7. Colon, submucosa and vessel wall biopsy with amorphous eosinophilic material deposit, using hematoxylin and eosin stain. A) 4x lens; B) 40x lens.

Source: Own elaboration based on the data obtained in the study.




Figure 8. Colon biopsy, Congo red staining with salmon-colored deposits in the thickened wall of the vessels. 4x lens.

Source: Own elaboration based on the data obtained in the study.




Figure 9. Colon biopsy, Congo Red staining. Apple-green birefringence on the wall of the glasses under polarized light with 40x lens.

Source: Own elaboration based on the data obtained in the study.




Figure 10. Colon biopsy, aspirated bone marrow. 40x lens with plasmacytes, some atypical binucleate cells, eccentric nucleus, broad and basophilic cytoplasm.

Source: Own elaboration based on the data obtained in the study.

DISCUSSION

The clinical case presented here is part of the 15% of AL amyloidosis cases associated with multiple myeloma. (7) Probably, amyloid deposits are present in patients with myeloma in a lesser proportion and such cases are not documented because there is no active search for these deposits. However, this case is relevant due to its clinical presentation, including severe involvement of multiple organs,

onset with amyloidosis symptoms, development of myeloma with classic CRAB features on admission, and the diagnostic process represented by multiple differentials.

In a retrospective study conducted by the Mayo Clinic, of a total of 1596 patients, only 12 patients presented with myopathy, pseudohypertrophy, jaw claudication and creatine kinase concentration slightly increased to normal (6), so the specialists recommended measuring monoclonal protein during the evaluation of a patient with proximal non-inflammatory myopathy. (6) In a subsequent cohort of the same reference center, of 3 434 patients with AL amyloidosis treated between January 1995 and December 2015, 1.5% presented with muscle involvement, 22% myopathy only, 65% cardiac symptoms, 31% peripheral/autonomic neuropathy, 25% renal symptoms, 8% liver symptoms and 4% gastrointestinal symptoms. (10)

At the cardiac level, infiltration of the endocardium, atria and valves is found in amyloidosis, which generates contractile dysfunction due to restriction. (3,5) The most common early manifestation is dyspnea on exertion due to left ventricular diastolic dysfunction, which progresses to peripheral edemas and ascites. Atrial arrhythmia with thrombus formation (3), low blood pressure (due to decreased cardiac output and low peripheral tone), postural hypotension due to autonomic nerve disorder (3,5) and claudication of the jaw, legs and angina due to vascular involvement. For this, performing an electrocardiogram is recommended considering its low voltage, as well as an echocardiography with cardiomyocyte infiltration and magnetic resonance due to difficulty for draining the myocardium after gadolinium injection and a non-coronary pattern of increased gadolinium delay. Loop diuretics are the treatment of choice for this

condition because angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and beta-blockers are poorly tolerated due to hypotension. (3)

Respiratory involvement, although rare, can occur with diaphragm or phrenic nerve infiltration; some cases have been reported. (11) In this case, significant muscle weakness with respiratory failure was observed, although a post-mortem diaphragm biopsy could not be performed. Pulmonary parenchymal, diffuse interstitial and tracheobronchial involvement, along with pulmonary hypertension type 1 by infiltration of the pulmonary vasculature, may also be observed. (11-13)

The patient had gastrointestinal involvement (3.2% frequency) (2); nevertheless, colonoscopy showed ulcerations and friability of the mucosa, classic findings of amyloidosis together with thickening of the intestinal wall, polypoid protuberances, erosions and fine granular appearance of the mucosa. (14) Common symptoms are abdominal pain, esophageal reflux, constipation and nausea. Others include diarrhea, weight loss and early satiety, which may be caused by autonomic neuropathy, bacterial overgrowth or cardiac cachexia. Replacement of intestinal smooth muscle causes dysmotility, pseudo-obstruction and even ischemia secondary to vascular infiltration or ganglion cells depletion. (2) The most involved sites are the duodenum, the rectum and the esophagus. (5,15) Hepatomegaly may be a consequence of congestion or infiltration (by kappa chains, hard and non-pulsatile liver). (3,5) Management is symptomatic with antiemetics, prokinetics and nutritional support (15), but in this case, no medication worked.

Cutaneous and mucosal involvement is diverse; this patient presented with periorbital ecchymosis or "raccoon eyes", which is pathog-

nomonic when associated with macroglossia. Other manifestations described were petechiae, ecchymotic macules, plaques, papules and nodules that simulate amber, hemorrhagic, normochromic or non-pruritic vesicles, which can appear in eyelids, retroauricular area, lips, tongue, oral mucosa, neck, armpits, submammary, navel and inguinal and anogenital area; the latter can simulate condylomata. (4) The perivascular amyloid deposit produces vessel fragility and spontaneous wounds or wounds caused by minimal trauma, as in this patient.

Although AL amyloidosis presents with nephrotic syndrome caused by hyaline deposits in the mesangium, in the glomerular basement membrane, in small arteries and in the tubular basement membrane, the reported case presented with "myeloma kidney" (tubulopathy caused by light chain deposits). Amyloidosis should be suspected in patients with myeloma and nephrotic proteinuria due to albuminuria, infiltrative cardiomyopathy, autonomic neuropathy, hepatomegaly and symptoms of partial intestinal obstruction. (16) Hypoadrenalism or hypothyroidism is less common (8), but this patient presented with subclinical hypothyroidism with hypogonadism. Differential diagnosis is wide, so the amyloid type should be confirmed, as well as other hematological malignancies such as lymphomas, waldenstrom macroglobulinemia and POEMS syndrome, which should be ruled out. (17)

Diagnosis includes confirming paraproteinemia (around 90% of patients have it). Serum or urine electrophoresis sensitivity is approximately 50%, increasing to 80-90% with immunoelectrophoresis. (9) Histological confirmation by biopsy of the affected organ or subcutaneous fat has a sensitivity of 70-80%. (3) Hematoxylin and eosin show eosinophilic amorphous material, salmon red coloration in Congo red and apple green-birefringence in

polarized light. Immunohistochemistry shows up to 92% amyloid subtype depending on the availability of antibodies with some limitation for the determination of AL amyloid, which has been attributed to difficulties, on the one hand, in the detection of conformational differences of light chains and the characteristics of the antibody used (18) and, on the other, the limited availability in some centers of a very sensitive method such as immunofluorescence for luminescent derivatives of polythiophene conjugates and immunoelectromicroscopy with gold-labeled antibodies and fibrillar anti-proteins. (19) Currently, the gold standard is proteomic analysis of amyloid deposits by mass spectrometry, after microdissection of Congo red–positive deposits. (3)

The prognosis of the disease depends on the number of affected organs, and there are prognostic biomarkers such as NT-proBNP and troponin T. The median survival is 6 months with cardiac involvement, but modern therapies based on bortezomib, dexamethasone and cyclophosphamide, followed by autologous stem cell transplantation, have shown longer survival rates with complete hematologic remission, unlike the first schemes with melphalan and prednisone (3,8), and are now the most commonly used schemes.

Likewise, there are reports of cases with localized involvement of the tracheobronchial vesicle that have been successfully managed by external beam radiotherapy. (20) The treatment of this systemic pathology is to suppress the plasmatic cell clone with chemotherapy and, in some cases, perform autologous bone marrow transplantation while supporting measures are taken to maintain the function of the organs involved as in the case of this patient. However, the progress of the disease, the prolonged stay in the ICU and the need for multiple devices favored his fatal outcome.

CONCLUSION

AL amyloidosis is a plasma cell dyscrasia that may be associated with multiple myeloma. Its onset spectrum is diverse, so a high index of suspicion should be considered so that it is not ignored, leading to an advanced stage that can be deadly. New chemotherapy schemes and timely diagnosis help improving survival.

CONFLICT OF INTERESTS

None stated by the authors.

FUNDING

None stated by the authors.

REFERENCES

1. **Blancas-Mejía LM, Ramírez-Alvarado M.** Systemic amyloidoses. *Annu Rev Biochem.* 2013;82:745-74. <http://doi.org/f474t9>.
2. **Gaduputi V, Badipatla K, Patel H, Tariq H, Ihimoyan A.** Primary systemic amyloidosis with extensive gastrointestinal involvement. *Case Rep Gastroenterol.* 2013;7(3):511-5. <http://doi.org/crsr>.
3. **Falk RH, Alexander KM, Liao R, Dorbala S.** AL (Light-Chain) Cardiac Amyloidosis. A Review of Diagnosis and Therapy. *J Am Coll Cardiol.* 2016;68(12):1323-41. <http://doi.org/crss>.
4. **Mendoza-Plata N, Ruíz AC, Pinto LF, Vásquez-Ochoa LA, Arredondo-Ossa MI.** Manifestaciones cutáneas de amiloidosis sistémica en tres pacientes. *MEDICINA U.P.B.* 2013;32(2):178-82.
5. **Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al.** Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis,

- Tours, France, 18-22 April 2004. *Am J Hematol*. 2005;79(4):319-28. <http://doi.org/ffv6dj>.
6. **Gertz MA, Kyle RA.** Myopathy in primary systemic amyloidosis. *J Neurol Neurosurg Psychiatry*. 1996;60(6):655-60. <http://doi.org/ckhqj9>.
 7. **Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al.** Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. *J Clin Oncol*. 2013;31(34):4319-24. <http://doi.org/crst>.
 8. **Pereira M, Afonso L, Fernandes G, Araújo R.** Multiple Myeloma and Amyloidosis Presenting as a Restrictive Lung Disease with Respiratory Failure. *Clin Med Rev Case Rep*. 2016;3(2):91.
 9. **Chapin JE, Kornfeld M, Harris A.** Amyloid myopathy: characteristic features of a still underdiagnosed disease. *Muscle Nerve*. 2005;31(2):266-72. <http://doi.org/cnb7sc>.
 10. **Muchtar E, Derudas D, Mauermann M, Liewluck T, Dispenzieri A, Kumar SK, et al.** Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. *Mayo Clin Proc*. 2016;91(10):1354-61. <http://doi.org/f87mn8>.
 11. **Novikov A, Holzer H, DeSimone RA, Abu-Zeinah G, Pisapia DJ, Mark TM, et al.** Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature. *Case Reports in Oncological Medicine*. 2015;2015:1-4. <http://doi.org/gccdq6>.
 12. **Ashe J, Borel CO, Hart G, Humphrey RL, Derrick DA, Kuncel RW.** Amyloid myopathy presenting with respiratory failure. *J Neurol Neurosurg Psychiatry*. 1992;55(2):162-5. <http://doi.org/c49p38>.
 13. **Dingli D, Utz JP, Gertz MA.** Pulmonary hypertension in patients with amyloidosis. *Chest*. 2001;120(5):1735-8. <http://doi.org/db53g5>.
 14. **Isomoto H, Kamo Y, Chen CC, Nakao K.** Clinical management of gastrointestinal amyloidosis. *Open Journal of Gastroenterology*. 2012;2:155-62. <http://doi.org/crsv>.
 15. **Cowan AJ, Skinner M, Seldin DC, Berk JL, Lichtenstein DR, O'Hara CJ, et al.** Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. *Haematologica*. 2013;98(1):141-6. <http://doi.org/f4krpp>.
 16. **Bahlis NJ, Lazarus HM.** Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? *Bone Marrow Transplant*. 2006;38(1):7-15. <http://doi.org/bb5jdf>.
 17. **Friedman Y, Paul JT, Turley J, Hazrati LN, Munoz D.** Axial myopathy due to primary amyloidosis. *Muscle Nerve*. 2007;36(4):542-6. <http://doi.org/bxmb3z>.
 18. **Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, et al.** Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. *Blood*. 2012;119(2):488-93. <http://doi.org/cs5px>.
 19. **Wechalekar AD, Gillmore JD, Hawkins PN.** Systemic amyloidosis. *Lancet*. 2016;387(10038):2641-54. <http://doi.org/f8rvjf>.
 20. **Cooper CT, Greene BD, Fegan JE, Rovira D, Gertz MA, Marcus DM.** External beam radiation therapy for amyloidosis of the urinary bladder. *Pract Radiat Oncol*. 2018;8(1):25-7. <http://doi.org/crsw>.